semaglutide for kidney failure Ozempic picks up FDA indication to treat chronic disease Semaglutide: A Breakthrough for Chronic

For instance, in a six-month randomized controlled trial of 72 patients with Friedreichs ataxia (a neurodegenerative disorder characterized by mitochondrial iron accumulation), 20 mg/kg/day DFP was well tolerated but higher doses (40 and 60 mg/kg/day) were associated with increased adverse events and worsening of ataxia symptoms (Pandolfo et al., 2014)

It is generating extraordinary clinical interest because the Phase 3 trial data published on 21 May 2026 shows weight loss results that no licensed medication has achieved before

Their semaglutide formulation is straightforward and well-established

Almost all regained

Close monitoring of mood, body image concerns, and eating behaviors during the rebound phase supports safe transition